Related Experiment Video
Updated: Apr 28, 2026
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
Targeting myeloid differentiation 2 for treatment of sepsis
Guangjie Duan1, Jiang Zhu1, Jianhua Xu1
1Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Abstract:
Sepsis continues to be a leading cause of intensive care unit (ICU) death. Gram-negative bacteria are among the most important pathogens of sepsis and their LPS content is regarded to be an important stimulator that elicits the systemic inflammatory reaction. MD-2 is a small secreted glycoprotein that can bind to both the hydrophobic portion of LPS and to the extracellular domain of TLR4. The interaction between MD-2 and LPS bridges the two TLR4 molecules and induces the dimerization of LPS-MD-2-TLR4, which forms the structural basis for biological functions of TLR4/MD-2 complex. Due to its essential role in mediating the interaction between LPS and TLR4, MD-2 has been extensively explored as a therapeutic target for treatment of inflammatory disorders such as sepsis. Eritoran is a synthetic tetraacylated lipid A that binds directly to MD-2 and antagonizes LPS binding to the same site. Although eritoran showed positive results in phase I and phase II clinical trials of severe sepsis, a phase III clinical study for severe sepsis has failed. More effective therapeutic strategies are in need to treat this devastating clinical disorder.
Insights
Sepsis, a major ICU killer, involves Gram-negative bacteria and lipopolysaccharide (LPS) stimulating Toll-like receptor 4 (TLR4). MD-2 protein mediates this interaction, but therapies like eritoran targeting it have failed, necessitating new strategies.
Area of Science:
- Immunology
- Microbiology
- Critical Care Medicine
Background:
- Sepsis remains a primary cause of intensive care unit mortality.
- Gram-negative bacteria, through lipopolysaccharide (LPS), are key sepsis pathogens.
- The Toll-like receptor 4 (TLR4)/MD-2 complex is crucial for mediating LPS-induced inflammatory responses.
Purpose of the Study:
- To explore the role of MD-2 in LPS-mediated TLR4 activation in sepsis.
- To review the therapeutic potential of targeting the MD-2/LPS interaction for sepsis treatment.
- To highlight the need for novel therapeutic strategies following the failure of eritoran in Phase III trials.
Main Methods:
- Review of existing literature on sepsis pathogenesis, LPS, MD-2, and TLR4.
- Analysis of the molecular interactions between LPS, MD-2, and TLR4.
- Examination of clinical trial data for MD-2 targeting agents, specifically eritoran.
Main Results:
- MD-2 is essential for LPS binding to TLR4, initiating a cascade of inflammatory signals.
- Eritoran, an MD-2 antagonist, demonstrated efficacy in early sepsis trials but failed in Phase III.
- The failure of eritoran suggests complex mechanisms or limitations in targeting the LPS-MD-2-TLR4 pathway.
Conclusions:
- Targeting the LPS-MD-2-TLR4 complex remains a promising avenue for sepsis therapy.
- Further research is required to develop more effective therapeutic agents for sepsis.
- Novel strategies are urgently needed to combat the high mortality associated with sepsis.
